Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified BUCY vs CLAG + modified BUCY in allo-HSCT for relapsed/refractory AML
ChiCTR-IPR-16009917Phase 4Not yet recruiting
- Sponsor
- Aerospace Center Hospital
- Start
- Jan 2017
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of busulfan, cyclophosphamide, cladribine, cytarabine and filgrastim in acute myeloid leukemia (AML) (2 arms), sponsored by Aerospace Center Hospital. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
busulfancyclophosphamidecladribinecytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IPR-16009917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009917.